valproic acid has been researched along with Heart Failure in 4 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the hazard for all-cause mortality and mortality due to heart failure (HF) between valproate (VPA) and levetiracetam (LEV)/lamotrigine (LTG) users in patients aged ≥ 65 with comorbidities of epilepsy and HF." | 8.12 | The Relationship Between Valproate and Lamotrigine/Levetiracetam Use and Prognosis in Patients With Epilepsy and Heart Failure: A Danish Register-Based Study. ( Gardella, E; Kragholm, K; Liang, D; Polcwiartek, C; Sessa, M, 2022) |
| "To compare the hazard for all-cause mortality and mortality due to heart failure (HF) between valproate (VPA) and levetiracetam (LEV)/lamotrigine (LTG) users in patients aged ≥ 65 with comorbidities of epilepsy and HF." | 4.12 | The Relationship Between Valproate and Lamotrigine/Levetiracetam Use and Prognosis in Patients With Epilepsy and Heart Failure: A Danish Register-Based Study. ( Gardella, E; Kragholm, K; Liang, D; Polcwiartek, C; Sessa, M, 2022) |
| " Replacement of phenytoin by valproic acid resulted in a 100-lb weight gain, exacerbation of sleep apnea, and right heart failure." | 3.73 | Lethal obesity associated with sodium valproate in a brain-injured patient. ( Althoff, RR; Black, DN; Daye, K; Pelletier, CA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, D | 1 |
| Gardella, E | 1 |
| Kragholm, K | 1 |
| Polcwiartek, C | 1 |
| Sessa, M | 1 |
| Chen, J | 1 |
| Wang, D | 1 |
| Fang, C | 1 |
| Zong, NC | 1 |
| Liem, DA | 1 |
| Cadeiras, M | 1 |
| Scruggs, SB | 1 |
| Yu, H | 1 |
| Kim, AK | 1 |
| Yang, P | 1 |
| Deng, M | 1 |
| Lu, H | 1 |
| Ping, P | 1 |
| Black, DN | 1 |
| Althoff, RR | 1 |
| Daye, K | 1 |
| Pelletier, CA | 1 |
4 other studies available for valproic acid and Heart Failure
| Article | Year |
|---|---|
The Relationship Between Valproate and Lamotrigine/Levetiracetam Use and Prognosis in Patients With Epilepsy and Heart Failure: A Danish Register-Based Study.
Topics: Aged; Anticonvulsants; Cohort Studies; Denmark; Epilepsy; Heart Failure; Humans; Lamotrigine; Leveti | 2022 |
Impaired cardiovascular function caused by different stressors elicits a common pathological and transcriptional response in zebrafish embryos.
Topics: Animals; Carbaryl; Cell Proliferation; Disease Models, Animal; Edema, Cardiac; Embryo, Nonmammalian; | 2013 |
Regulation of acetylation restores proteolytic function of diseased myocardium in mouse and human.
Topics: Acetylation; Animals; Chromatography, Liquid; Gene Expression Regulation; Heart Failure; Heart Trans | 2013 |
Lethal obesity associated with sodium valproate in a brain-injured patient.
Topics: Adult; Anticonvulsants; Brain Injuries; Epilepsy; Fatal Outcome; Heart Failure; Humans; Male; Obesit | 2005 |